Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway

Carcinogenesis

Volumn 35, Issue 12, 2014, Pages 2820-2830

  Morgado Palacin, Lucia ^a   Llanos, Susana ^a   Urbano Cuadrado, Manuel ^a   Blanco Aparicio, Carmen ^a   Megias, Diego ^b   Pastor, Joaquín ^a   Serrano, Manuel ^a  

^a Experimental Therapeutics Program   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AMINOACRIDINE; CID 765471; DNA DIRECTED RNA POLYMERASE; ETHACRIDINE; PROTEIN MDM2; PROTEIN P53; RIBOSOME DNA; RIBOSOME PROTEIN; ROTEIN RPL11; UNCLASSIFIED DRUG; CID-765471; DRUG; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NAPHTHYRIDINE DERIVATIVE; RIBOSOMAL PROTEIN L11; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ARTICLE; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; DNA TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RIBOSOME; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; METABOLISM; NORTHERN BLOTTING; OSTEOSARCOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACRIDINES; BLOTTING, NORTHERN; BLOTTING, WESTERN; BONE NEOPLASMS; COLONIC NEOPLASMS; DNA DAMAGE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOPRECIPITATION; NAPHTHYRIDINES; OSTEOSARCOMA; PHARMACEUTICAL PREPARATIONS; PROTO-ONCOGENE PROTEINS C-MDM2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923637652     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu220     Document Type: Article

References (32)

1. Thomson, E. et al. (2013) Eukaryotic ribosome biogenesis at a glance. J Cell Sci., 126, 4815-4821.
2. Deisenroth, C. et al. (2010) Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 29, 4253-4260.
3. Horn, H.F. et al. (2008) Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene, 27, 5774-5784.
4. Bursac, S. et al. (2012) Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc. Natl Acad. Sci. USA, 109, 20467-20472.
5. Fumagalli, S. et al. (2012) Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev., 26, 1028-1040.
6. Donati, G. et al. (2013) 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep., 4, 87-98.
7. Macias, E. et al. (2010) An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell, 18, 231-243.
8. Lawrence, M.S. et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505, 495-501.
9. De Keersmaecker, K. et al. (2013) Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet., 45, 186-190.
10. Dresios, J. et al. (2006) Eukaryotic ribosomal proteins lacking a eubacterial counterpart: important players in ribosomal function. Mol. Microbiol., 59, 1651-1663.
11. Teng, T. et al. (2013) Growth control and ribosomopathies. Curr. Opin. Genet. Dev., 23, 63-71.
12. Hein, N. et al. (2013) The nucleolus: an emerging target for cancer therapy. Trends Mol. Med., 19, 643-654.
13. Rubbi, C.P. et al. (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J., 22, 6068-6077.
14. Boisvert, F.M. et al. (2007) The multifunctional nucleolus. Nat. Rev. Mol. Cell Biol., 8, 574-585.
15. Burger, K. et al. (2010) Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem., 285, 12416-12425.
16. Llanos, S. et al. (2010) Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle, 9, 4005-4012.
17. Zhu, Y. et al. (2009) Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell, 35, 316-326.
18. Cui, D. et al. (2014) The ribosomal protein S26 regulates p53 activity in response to DNA damage. Oncogene, 33, 2225-2235.
19. Bunz, F. et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science, 282, 1497-1501.
20. Toledo, L.I. et al. (2011) A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol., 18, 721-727.
21. O'Donohue, M.F. et al. (2010) Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. J. Cell Biol., 190, 853-866.
22. Lam, Y.W. et al. (2007) Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins. Curr. Biol., 17, 749-760.
23. Kressler, D. et al. (2010) Driving ribosome assembly. Biochim. Biophys. Acta, 1803, 673-683.
24. Shav-Tal, Y. et al. (2005) Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. Mol. Biol. Cell, 16, 2395-2413.
25. Peltonen, K. et al. (2010) Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One, 5, e12996.
26. Dudgeon, D.D. et al. (2010) Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits. J. Biomol. Screen., 15, 766-782.
27. Wang, W. et al. (2005) Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol. Ther., 4, 893-898.
28. Peltonen, K. et al. (2014) A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell, 25, 77-90.
29. Lane, L.A. et al. (2011) Mass spectrometry reveals stable modules in holo and apo RNA polymerases I and III. Structure, 19, 90-100.
30. Drygin, D. et al. (2011) Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res., 71, 1418-1430.
31. Galdino-Pitta, M.R. et al. (2013) Niche for acridine derivatives in anticancer therapy. Mini Rev. Med. Chem., 13, 1256-1271.
32. Bywater, M.J. et al. (2012) Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell, 22, 51-65.